晨光生物 20250710 摘要 晨光生物 2025 年上半年净利润显著增长，预计为 1.74 亿至 2.04 亿元， 同比增长 117%至 154%，主要得益于棉子类业务扭亏为盈和植提业务 销量增长。二季度收入 17.44 亿至 20.44 亿元，同比增长-1%至 16%。 棉子类业务受益于行情回暖和公司对锁采购策略，上半年扭亏为盈。预 计三季度进入淡季，但四季度榨季开始后业务规模将回升。公司加强风 险管控，使其成为稳定现金流和利润的重要资产。 植提业务二季度保持良好恢复态势，尽管辣椒红等产品价格下降，但下 游需求快速增长带动销量增加，毛利率显著改善。预计三季度延续此趋 势，受益于供给侧结构性优化和需求侧天然色素替代。 美国 FDA 禁用石油基合成色素政策可能引发全球范围内的天然色素替代 浪潮，为晨光生物带来巨大市场机遇。公司已布局天然色素 20 多年， 通过提升性价比和技术创新推动天然色素消费量增长。 晨光生物正从生产企业向应用方案服务商转型，通过开发新型产品拓宽 应用领域，与乳制品、调理肉、火锅底料及饮料企业合作，不断丰富天 然植物提取物应用场景，提高产品性价比及使用便利性。 Q&A 2025 年上半年 ...

证券代码：300138 证券简称：晨光生物 晨光生物科技集团股份有限公司 投资者关系活动记录表 编号：2025-005 | | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | □现场参观 □一对一沟通 | | | √其他 （电话会议） 天风证券吴立/陈潇/林毓鑫、中金公司宗旭豪、信达证券赵雷、 | | | 财通证券吴文德、中信证券罗寅、方正证券谌保罗、申万宏源 | | | 王子昂、长江证券陈硕旸、西南证券杜雨聪、国泰海通蔡子慕、 | | 参与单位名称及 | 博时基金谢泽林、天弘基金田继龙、广发基金顾益辉、华泰资 | | 人员姓名 | 管陈少楠、泓德基金郑名洋、PleiadInvestmentAdvisors | | | LimitedSimonSun、Sequoia Capital 闫慧辰、源乘私募曾尚、 | | | 彬元资本周振兴等 67 名投资者。 | | 时间 | 2025 年 07 月 10 日 | | 地点 | 河北省邯郸市曲周县城晨光路 1 号会议室 | | | 其他各电话会议方 ...

Core Viewpoint - The company, Morning Bio, is experiencing a significant recovery in its performance, with a projected net profit increase of 102.33% to 132.38% in the first half of 2025 compared to the same period last year, primarily driven by the recovery of its cottonseed business and growth in plant extraction products [1][4]. Group 1: Financial Performance - Morning Bio expects a net profit of 202 million to 232 million yuan in the first half of 2025, compared to 99.83 million yuan in the same period last year [1][4]. - In 2023, the company achieved a record high revenue of 6.872 billion yuan and a net profit of 480 million yuan [3]. - In 2024, the company faced challenges with a net profit drop of 80.39% to 94.05 million yuan due to significant losses in the cottonseed business [3][4]. Group 2: Business Segments - The recovery in the cottonseed business is attributed to improved market conditions, with the company planning to increase the protein content in its products to enhance profitability [4][7]. - The plant extraction business, including products like chili red, chili essence, and stevia glycosides, has shown a year-on-year increase in gross profit, contributing to overall performance improvement [1][4]. Group 3: Industry Position - Morning Bio has become the largest listed company in China's plant extraction industry and ranks among the top tier globally, competing with international leaders [5][6]. - The company has developed proprietary technologies for extracting chili red pigment, positioning China as a leading producer in this sector [5]. Group 4: Technological Advancements - The company has invested nearly 10 million yuan in process improvements for its cottonseed business and over 3 million yuan in upgrading its stevia production line, achieving a 30% reduction in production costs [7]. - The first quarter of 2025 saw the plant extraction business generate 867 million yuan in revenue, a 13.78% increase year-on-year, attributed to a successful volume-based pricing strategy [7].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% relative to the industry index in the next six months [5][18]. Core Views - The company is experiencing a performance recovery that exceeds expectations, with growth potential still present in the mid-term [1]. - The recovery in the cottonseed business is a significant factor contributing to the strong performance in the first half of the year, supported by favorable market conditions [2]. - The company is positioned as a leader in the plant extract sector, with stable profitability from key products and a strategic plan that is progressing steadily [9]. Financial Summary - **Revenue Forecast**: The company expects to achieve revenues of 6,872 million yuan in 2023, with a growth rate of 9.1%. Projections for 2024 and 2025 show revenues of 6,994 million yuan and 7,064 million yuan, respectively, with growth rates of 1.8% and 1.0% [1]. - **Net Profit**: The forecasted net profit for 2023 is 480 million yuan, with a year-on-year growth of 10.5%. However, a significant drop is expected in 2024, with a projected net profit of 94 million yuan, reflecting an 80.4% decline. A recovery is anticipated in 2025, with a net profit of 346 million yuan, representing a growth of 268.1% [1]. - **Earnings Per Share (EPS)**: The latest diluted EPS is projected to be 0.99 yuan in 2023, dropping to 0.19 yuan in 2024, and recovering to 0.72 yuan in 2025 [1][9]. - **Price-to-Earnings (P/E) Ratio**: The P/E ratio is expected to be 13.7 in 2023, soaring to 70.0 in 2024, and then stabilizing at 19.0 in 2025 [1][9]. Market Conditions - The cottonseed market is showing a stable upward trend, which has positively impacted the company's performance in the first half of the year [2]. - The company is expected to benefit from multiple growth drivers, including increased product volume, improved efficiency in overseas plantations, and a growing demand for health products [2].

Core Viewpoint - The company, Morning Bio (300138.SZ), anticipates significant growth in its financial performance for the first half of 2025, driven primarily by the recovery in its cottonseed business and steady growth in its plant extraction segment [1][2]. Financial Performance Summary - The company expects to achieve revenue between 3.46 billion to 3.76 billion yuan, reflecting a year-on-year change of -0.89% to 7.71% [1]. - The projected net profit attributable to shareholders is estimated to be between 202 million to 232 million yuan, indicating a substantial year-on-year increase of 102.33% to 132.38% [1]. - The expected non-recurring net profit ranges from 174 million to 204 million yuan, with a remarkable growth rate of 117.40% to 154.88% compared to the previous year [1]. Business Segment Performance - The recovery in the cottonseed business is identified as the main factor influencing the company's performance, transitioning from losses to profitability due to improved market conditions [1]. - The plant extraction business, including products like chili red, chili essence, and steviol glycosides, has also contributed to the overall profit growth, with significant year-on-year increases in gross profit [1]. Strategic Insights - The company has committed to a locked-in operating model, which has effectively mitigated risks associated with price fluctuations in the cottonseed market, leading to a turnaround in profitability [1][2]. - The company anticipates that high prices for cottonseed protein and the implementation of new standards for lutein will provide ongoing growth momentum in the second half of the year [2].

Q2 业绩超预期，棉籽持续回暖，植提业务向好。单25Q2 看，预计公司营业收入为17.44-20.44 亿元， 同比-0.9%至+16.2%，预计公司归母净利润为0.93-1.23 亿元，同比+51.1%至+100.1%，预计公司扣非归 母净利润为0.78-1.08 亿元，同比+147.5%至+242.6%。25H1 棉籽类业务行情回暖，公司严格执行对锁经 营模式，同比实现扭亏为盈；植提类业务中，辣椒红、辣椒精、甜菊糖苷等植提类业务毛利润均实现同 比增长，植提呈现向好趋势 短期看棉籽业务盈利修复，中长期植提业务景气度向上。棉籽业务方面，25 年，公司在严格执行对锁 经营模式的情况下，锁定了加工环节的利润，全年盈利改善的趋势较强；植提业务方面，当前多个植提 产品价格处于相对低位，有望逐渐企稳向好，25 年4 月，美国FDA 宣布计划将于26 年底前逐步停止使 用石油基合成的食品色素，我们认为美国FDA 此举将有望推动全球人工色素的加速淘汰，天然色素占 比将提升，推动公司的辣椒红、叶黄素、番茄红素等天然色素的需求增长，植提业务的毛利率有望提 升。 盈利预测与投资评级：公司作为植物提取物龙头企业，植提技术行业领先， ...

Group 1 - Huaguang Huaneng's stock has experienced five consecutive trading limits, with a cumulative turnover rate of 29.41% over the past five trading days, indicating potential irrational speculation risk [3] - The company confirms that its production and operational activities are normal, with no significant changes in its fundamentals or business structure [3] Group 2 - Andeli's actual controller Wang An transferred 90% of the shares of BVI Pingan to his daughter Wang Meng, but this transfer does not affect the company's shareholding structure or governance [4] - The controlling shareholder and actual controllers remain unchanged, ensuring the company's governance structure and ongoing operations are unaffected [4] Group 3 - Suntech's indirect controlling shareholder, Suntech Holdings, has had 4.26 million unrestricted circulating shares (8.51% of its holdings, 0.19% of total shares) judicially disposed of, but this is not expected to impact the company's daily operations [5] Group 4 - Three Gorges Energy reported a total power generation of 39.314 billion kWh in the first half of 2025, representing an 8.85% year-on-year increase [6] - The company generated 19.531 billion kWh in the second quarter of 2025, a 6.24% increase compared to the same period last year [6] Group 5 - New Zhonggang's stock has experienced four consecutive trading limits, with no significant media reports or market rumors affecting its stock price [7] - The company confirms that its production and operational status is normal, with no major adjustments in market environment or industry policies [7] Group 6 - ST Yazhen's controlling shareholder Wu Tao's tender offer for 55.1779 million shares (21.00% of total shares) at a price of 5.68 yuan per share has reached its deadline, leading to a one-day suspension of trading [8] Group 7 - Zhongli's wholly-owned subsidiary plans to invest 478 million yuan in a smart logistics equipment project in Jiangsu, with the project covering approximately 120 acres [9][10] Group 8 - Xianda expects a net profit of 130 million to 150 million yuan for the first half of 2025, a year-on-year increase of 2443.43% to 2834.73%, driven by rising product prices and improved operational efficiency [12] - The company's main product, Oxyfluorfen, has seen a price increase, contributing to higher gross margins [12] Group 9 - Morninglight Bio expects a net profit of 202 million to 232 million yuan for the first half of 2025, a year-on-year increase of 102.33% to 132.38%, primarily due to the recovery of cottonseed business [13] Group 10 - Xinlian Electronics anticipates a net profit of 166 million to 198 million yuan for the first half of 2025, reversing a loss from the previous year, largely due to increased non-recurring gains [14] Group 11 - Wohua Pharmaceutical expects a net profit of 37 million to 53 million yuan for the first half of 2025, a year-on-year increase of 233.89% to 378.27%, attributed to improved market adaptation and cost control [15] Group 12 - Yonghe expects a net profit of 255 million to 280 million yuan for the first half of 2025, a year-on-year increase of 126.30% to 148.49%, driven by rising refrigerant prices [16] Group 13 - Shanghai Pharmaceuticals anticipates a net profit of 4.45 billion yuan for the first half of 2025, a year-on-year increase of approximately 52%, mainly due to the acquisition of a 10% stake in Shanghai Hutchison Pharmaceuticals [17] Group 14 - Jingneng Real Estate expects a net loss of 190 million to 210 million yuan for the first half of 2025, primarily due to reduced project turnover and increased expenses [18] Group 15 - Fengfan has won a bid for a project with a value of approximately 337 million yuan from Southern Power Grid, accounting for 10.45% of the company's audited revenue for 2024 [19] Group 16 - Longjian has been awarded a joint bid for a project worth 362 million yuan, with the company responsible for 99.39% of the work [20]

本次业绩预告是公司财务部门初步测算的结果，具体数据将在公司2025年半 年度报告中详细披露，敬请广大投资者谨慎决策，注意投资风险。 特此公告 证券代码：300138 证券简称：晨光生物 公告编号：2025—067 晨光生物科技集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 本报告期 上年同期 项 目 （2025 年 1—6 月） （2024 年 1—6 月） 营业收入 349,092.99 万元 比上年同期增长：-0.89%至 7.71% 归属于上市公司股东 盈利：20,200 万元—23,200 万元 盈利：9,983.46 万元 的净利润 比上年同期增长：102.33%至 132.38% 归属于上市公司股东 盈利：17,400 万元—20,400 万元 扣除非经常性损益后 盈利：8,003.77 万元 的净利润 比上年同期增长：117.40%至 154.88% 二、业绩预告预审计情况：本次业绩预告相关数据未经注册会计师审计。 三、业绩变动原因说明 的主要影响因素；辣椒红、辣椒精、甜菊糖苷等植提类业务实现的毛利润均同比 ...

Core Viewpoint - The company, Morning Bio-Technology Group Co., Ltd., is actively engaging with investors to discuss its business development, market strategies, and future plans, indicating a focus on transparency and investor relations [1]. Group 1: Cottonseed Business - The chairman stated that last year's losses in the cottonseed business were primarily due to market fluctuations and operational issues, but the company has implemented strategies to lock in profits during processing, effectively controlling risks [3]. - The company has achieved normal production and delivery for the current quarter's cottonseed procurement and plans to enhance gross margins by increasing protein content and optimizing production management [3]. - Although the company withdrew its application for listing the cottonseed segment on the Beijing Stock Exchange due to market changes, it remains open to pursuing this business development in the future if suitable opportunities arise [3]. Group 2: Lutein Business - The company’s secretary noted that lutein prices are currently low but are expected to rise in the future, with the company leveraging its advantages in raw materials, such as self-built planting bases and improved breeding technology, to expand market share [3]. - Despite a decrease in raw material purchase prices affecting farmers' planting enthusiasm, the company believes that long-term base construction will gradually increase its market share in the lutein sector [3]. - The trend of natural colorants replacing synthetic ones presents significant opportunities for the industry, and the company plans to actively monitor market changes to seize these opportunities [3]. Group 3: Chili Business - The company highlighted that the price sensitivity of users to chili red pigment, a food additive, is low, with price changes mainly influenced by raw material costs [4]. - The company enjoys a significant cost advantage due to high processing yields compared to peers, and the domestic chili raw material advantage has led to an increase in market share in the chili pigment business [4]. - The company is advancing its planting base in Myanmar, which is ideal for marigold cultivation, to enhance its raw material supply capabilities [4]. Group 4: Future Outlook - The company will continue to focus on its core business by enhancing core competitiveness through technological innovation, market expansion, and industry chain integration [4]. - The company emphasizes the importance of closely monitoring market dynamics and policy changes to flexibly adjust strategic directions, ensuring stable business progress [4].

证券研究报告 | 行业定期报告 2025 年 05 月 12 日 成长赛道仍具看点，关注股东大会催化 食品饮料行业周报（5.11） 消费品/食品饮料 财报季正式收官，白酒高端与区域龙头平稳落地，25 年行业目标普遍审慎。大 众品表现分化，饮料/零食/宠物食品等成长性赛道仍具看点，啤酒乳制品实现 复苏，调味品相对平淡，龙头业绩更优。本周策略会反馈来看，白酒仍然承 压，大众品 4 月整体动销平稳，乳品/调味品期待 Q2 改善。 核心公司跟踪：短期白酒仍然承压，大众品整体平稳 舍得酒业：Q2 整体需求环比承压明显。舍得主品在宴席场景有双位数增 长，但在商务场景仍相对承压，预计二季度后会有好转，但行业调整期预 计仍将持续。25 年公司在去库存后轻装上阵。 水井坊：Q2 环比压力增加，淡季需求回落明显。25 年将完成井台产品的 迭代，推出 18、28 号产品。终端拓展上，2024 年新增 1 万家门店， 25Q1 新增 2.5 万家，总门店数达到 7-8 万家，根据不同门店情况制定销 售任务。分市场来看，河北增长状况良好，内蒙、山东增速也较快。 伊利股份：Q2 延续改善，奶粉双线驱动。春节动销超预期，Q1 实现正增 长 ...